RJA
ARRY

Raymond James & Associates’s Array Biopharma Inc ARRY Stock Holding History

Raymond James & Associates’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-12,518
Closed -$305K – 3811
2019
Q1 		$305K Buy
12,518
+2,221
+22% +$46.2K ﹤0.01% 2973
2018
Q4 		$147K Buy
+10,297
New +$156K ﹤0.01% 3226
2017
Q1 		– Sell
-10,400
Closed -$91K – 3446
2016
Q4 		$91K Hold
10,400
– – ﹤0.01% 3041
2016
Q3 		$70K Buy
+10,400
New +$40.2K ﹤0.01% 3049

Other funds holding ARRY

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Raymond James & Associates's ARRY Position: Q2 2019 in Review

Raymond James & Associates sold out of Array Biopharma Inc (ARRY) in Q2 2019, closing a stake of 12,518 shares — an estimated $305K sold.

Raymond James & Associates first reported a position in ARRY in Q3 2016 and held it in 4 quarters. The position peaked at $305K in Q1 2019. 318 funds tracked by Wall St. Rank hold ARRY as of Q2 2019.

  • Raymond James & Associates reported no remaining Array Biopharma Inc position as of Q2 2019 after selling out during the quarter.
  • Raymond James & Associates sold 12,518 Array Biopharma Inc shares in Q2 2019, an estimated $305K.
  • Raymond James & Associates first reported a position in Array Biopharma Inc in Q3 2016 and held it in 4 quarters.
  • Raymond James & Associates's Array Biopharma Inc position peaked at $305K in Q1 2019.
  • 318 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q2 2019.

Based on Raymond James & Associates's 13F filing for Q2 2019, filed 6 Aug 2019.